Summary & Overview
CPT 0082U: NextGen Precision™ Urine Drug Interaction Screening
CPT code 0082U identifies a Proprietary Laboratory Analyses (PLA) test — NextGen Precision™ from Precision Diagnostics — a presumptive urine drug test that screens instrumentally for the severity of possible interactions among 90+ drugs, metabolites, and other substances. As a PLA code, 0082U maps to a single manufacturer-specific test and is used when reporting that specific assay.
This code matters nationally as PLA-designated tests are increasingly used in precision toxicology and medication management, creating distinct billing flows and coverage considerations compared with non-proprietary laboratory assays. Key payers discussed in this profile include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Payer coverage policies and reimbursement practices for PLA tests vary by plan and often hinge on medical necessity criteria and documentation of clinical utility.
Readers will find a concise overview of clinical context (presumptive urine drug interaction screening), typical service and site of service, and the payers addressed. The report summarizes benchmarks where available, notes policy and coding considerations relevant to PLA tests, and provides context for coding and claims submission. Data not available in the input will be noted as such in relevant sections.
Billing Code Overview
CPT code 0082U is a Proprietary Laboratory Analyses (PLA) code for the NextGen Precision™ test from Precision Diagnostics. The code describes a presumptive drug test that uses instrumented chemistry analyzers to analyze a urine specimen for the severity of possible interactions among 90 or more drugs, drug breakdown products, or other substances.
Service Type: Proprietary laboratory drug interaction screening using instrumented chemistry analyzers
Typical Site of Service: Clinical laboratory or outpatient laboratory setting where urine specimens are collected and analyzed
Clinical & Coding Specifications
Clinical Context
A typical patient is a 45-year-old outpatient referred by a primary care physician or pain management specialist for a urine-based presumptive drug interaction screen after a medication review identified polypharmacy risks. The patient presents to an outpatient laboratory or hospital outpatient collection center; a urine specimen is collected under standard chain-of-custody or routine specimen handling depending on clinic policy. The specimen is analyzed by an instrumented chemistry analyzer using the NextGen Precision™ assay to screen for severity of possible interactions among 90+ drugs, metabolites, or substances. Results are reported to the ordering clinician to inform medication reconciliation, opioid stewardship, substance use evaluation, or adverse drug reaction assessment. Typical workflow steps: order placed by clinician, patient check-in at outpatient laboratory or hospital outpatient department, urine specimen collected and labeled, specimen received and processed in the laboratory performing the NextGen Precision™ test, instrumented chemistry analysis performed, result interpretation and report generated, clinician reviews results and documents findings in the patient medical record.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier; standard reporting | Use when no additional modifier is necessary and the service is reported as usual. |